Please type a plus sign (+) inside this box -

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

34

TRANSMIT	TAL
FORM	

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number 09/589,730 06/08/2000 **Filing Date First Named Inventor** KENISON, Dale C. 1616 Group Art Unit LEVY, Neil S. **Examiner Name** 70021220.0031 Attorney Docket Number

	ENCLOSURES (check all that apply)		
Fee Transmittal Form	Assignment Papers (for an Application) After Allowance Communication to Group		
Fee Attached	Drawing(s) Appeal Communication to Board of Appeals and Interferences		
X Amendment / Reply	Licensing-related Papers Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)		
After Final	Petition Proprietary Information		
Affidavits/declaration(s	Petition to Convert to a Provisional Application Status Letter		
Extension of Time Request	Power of Attorney, Revocation Change of Correspondence Address X Other Enclosure(s) (please identify below):		
Express Abandonment Reque	Terminal Disclaimer Return Postcard Request for Refund		
Information Disclosure Statem	CD, Number of CD(s)		
Certified Copy of Priority Document(s)	Remarks		
Response to Missing Parts/ The Commissioner is hereby authorized			
Incomplete Application Response to Missing Parts Communication or credit any overpayment to			
under 37 CFR 1.52 or 1			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm or Individual name Sonne	chein, Nath & Rosenthal by Lara Dickey Lewis		
Signature Lau	Reg. No. 48,161		
Date Aug	et 2, 2002		

The second secon	
mainman-envelope-addressed to Commissioner tor ratems, washington, po-2025 - on the date	
To the State of th	
Signature	
Olginataro Daton Sala	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PECELVED TOOLSON Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number



Certificate of Mailing by EXPRESS MAIL under 37 CFR 1.10

I hereby certify that the following documents:

Transmittal Form (1 pg); Certificate of Mailing by Express Mail (1 pg); Amendment responsive to OA of 02/05/2002 (12 pgs plus 2 pgs. Appendix A & 3 pgs. Appendix B & 9 pgs Exhibit A & 6 pgs Exhibit B; and Return Postcard

are being deposited with the United States Postal as "Express Mail Post Office to Addressee" and addressed to:

> **Commissioner for Patents BOX NON-FEE AMENDMENT** Washington, D.C. 20231

On	August 2, 2002
	Date
	Joa Thans
	Signature
	Lea T. Page
	Typed or printed name of person signing Certificate
	Typed of printed flame of person signing definitions
	EL 716466885 US
	EXPRESS MAIL NO.

Note: Each paper must have its own certificate of mailing by Express Mail, or this certificate must identify each submitted paper.

Docket No. 70021220.0031

<u>IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</u>

pplication of:

KENISON, DALE C., et al.) Group Art Unit No. 1616

Application No.: 09/589,730) Examiner: Levy, Neil S.

Filing Date: June 8, 2000

Title: GROWTH PROMOTING

PHARMACEUTICAL IMPLANT

BOX NON-FEE AMENDMENT

Commissioner for Patents Washington, D.C. 20231

AMENDMENT AND RESPONSE TO FEBRUARY 5, 2002 OFFICE ACTION

In response to the Office Action dated February 5, 2002, amendment and reconsideration of the above-referenced application are respectfully requested.

In the Claims, please substitute claims 1-4 and 10-12 with the following:

- 1. (Amended) A solid bio-accessible implant for placement under the skin of an animal comprising:
 - a synergistically effective amount of a growth stimulating agent; and a synergistically effective amount of a supplemental agent; wherein said agents synergistically combine to promote growth in an animal.
- 2. (Amended) The implant according to claim 1 wherein said growth stimulating agent is selected from the group consisting of trenbolone acetate, estradiol, estradiol benzoate, zeranol, testosterone propionate, progesterone, derivatives and combinations thereof.
- 3. (Amended) The implant according to claim 1 wherein said supplemental agent is selected from the group consisting of parasiticides, estrus-suppressing compositions, antibiotics, somatotropins, gonadotropins, derivatives and combinations thereof.

PI